Vertex Pharmaceuticals
VRTX
933 hedge funds and large institutions have $41.8B invested in Vertex Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 97 funds opening new positions, 358 increasing their positions, 348 reducing their positions, and 130 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 358 | Existing positions reduced: 348
0.8% less ownership
Funds ownership: 90.06% → 89.26% (-0.8%)
5% less call options, than puts
Call options by funds: $501M | Put options by funds: $527M
4% less funds holding
Funds holding: 976 → 933 (-43)
11% less capital invested
Capital invested by funds: $46.7B → $41.8B (-$4.91B)
25% less first-time investments, than exits
New positions opened: 97 | Existing positions closed: 130
60% less funds holding in top 10
Funds holding in top 10: 15 → 6 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$967M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$525M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$292M |
| 4 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$281M |
| 5 |
Two Sigma Investments
New York
|
+$187M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.44B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$430M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$420M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$281M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$187M |
VRTX Hedge Fund Activity: Q3 2021 in Review
933 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2021, worth a combined $41.8B — down 11% from $46.7B a quarter earlier.
Sellers outnumbered buyers: 130 funds closed out of VRTX and 97 opened new positions — a net loss of 33 holders — while 348 trimmed existing stakes and 358 added.
The largest buyer was Loomis, Sayles & Company, adding an estimated $967M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.44B.
- 933 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2021, down from 976 in Q2 2021.
- Funds reported $41.8B of Vertex Pharmaceuticals stock for Q3 2021, down 11% quarter-over-quarter.
- 97 funds opened new Vertex Pharmaceuticals positions in Q3 2021 and 130 closed out, a net change of -33 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2021 was Loomis, Sayles & Company, an estimated $967M added.
- The largest Vertex Pharmaceuticals seller in Q3 2021 was T. Rowe Price Associates, an estimated $1.44B sold.
Based on aggregated 13F filings for Q3 2021.